Mutations in the phosphatidylinositol 3-kinase pathway

Role in tumor progression and therapeutic implications in breast cancer

Todd W. Miller, Brent N. Rexer, Joan T. Garrett, Carlos L. Arteaga

Research output: Contribution to journalReview article

222 Citations (Scopus)

Abstract

Mutations in genes that constitute the phosphatidylinositol 3-kinase (PI3K) pathway occur in >70% of breast cancers. Clinical and experimental evidence suggest that PI3K pathway activation promotes resistance to some of the current breast cancer therapies. PI3K is a major signaling hub downstream of human epidermal growth factor receptor (HER)2 and other receptor tyrosine kinases. PI3K activates AKT, serum/glucocorticoid regulated kinase (SGK), phosphoinositide-dependent kinase 1 (PDK1), mammalian target of rapamycin (mTOR), and several other molecules involved in cell cycle progression and survival. In estrogen receptor (ER)+ breast cancer cells, PI3K activation promotes estrogen-dependent and -independent ER transcriptional activity, which, in turn, may contribute to anti-estrogen resistance. Activation of this pathway also confers resistance to HER2-targeted therapies. In experimental models of resistance to anti-estrogens and HER2 inhibitors, pharmacological inhibition of PI3K/AKT/mTOR has been shown to overcome drug resistance. Early clinical data suggest that combined inhibition of either HER2 or ER plus inhibition of the PI3K pathway might be an effective strategy for treatment of respective HER2+ and ER+ breast cancers resistant to standard therapies. Here, we review alterations in the PI3K pathway in breast cancer, their association with therapeutic resistance, and the state of clinical development of PI3K pathway inhibitors.

Original languageEnglish (US)
Article number224
JournalBreast Cancer Research
Volume13
Issue number6
DOIs
StatePublished - Nov 1 2011

Fingerprint

Phosphatidylinositol 3-Kinase
Breast Neoplasms
Mutation
Estrogen Receptors
Neoplasms
Estrogens
Therapeutics
Sirolimus
1-Phosphatidylinositol 4-Kinase
Receptor Protein-Tyrosine Kinases
Drug Resistance
Cell Survival
Cell Cycle
Theoretical Models
Pharmacology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mutations in the phosphatidylinositol 3-kinase pathway : Role in tumor progression and therapeutic implications in breast cancer. / Miller, Todd W.; Rexer, Brent N.; Garrett, Joan T.; Arteaga, Carlos L.

In: Breast Cancer Research, Vol. 13, No. 6, 224, 01.11.2011.

Research output: Contribution to journalReview article

@article{7ccab98369f343118c28e96b3361d440,
title = "Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer",
abstract = "Mutations in genes that constitute the phosphatidylinositol 3-kinase (PI3K) pathway occur in >70{\%} of breast cancers. Clinical and experimental evidence suggest that PI3K pathway activation promotes resistance to some of the current breast cancer therapies. PI3K is a major signaling hub downstream of human epidermal growth factor receptor (HER)2 and other receptor tyrosine kinases. PI3K activates AKT, serum/glucocorticoid regulated kinase (SGK), phosphoinositide-dependent kinase 1 (PDK1), mammalian target of rapamycin (mTOR), and several other molecules involved in cell cycle progression and survival. In estrogen receptor (ER)+ breast cancer cells, PI3K activation promotes estrogen-dependent and -independent ER transcriptional activity, which, in turn, may contribute to anti-estrogen resistance. Activation of this pathway also confers resistance to HER2-targeted therapies. In experimental models of resistance to anti-estrogens and HER2 inhibitors, pharmacological inhibition of PI3K/AKT/mTOR has been shown to overcome drug resistance. Early clinical data suggest that combined inhibition of either HER2 or ER plus inhibition of the PI3K pathway might be an effective strategy for treatment of respective HER2+ and ER+ breast cancers resistant to standard therapies. Here, we review alterations in the PI3K pathway in breast cancer, their association with therapeutic resistance, and the state of clinical development of PI3K pathway inhibitors.",
author = "Miller, {Todd W.} and Rexer, {Brent N.} and Garrett, {Joan T.} and Arteaga, {Carlos L.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1186/bcr3039",
language = "English (US)",
volume = "13",
journal = "Breast Cancer Research",
issn = "1465-5411",
publisher = "BioMed Central",
number = "6",

}

TY - JOUR

T1 - Mutations in the phosphatidylinositol 3-kinase pathway

T2 - Role in tumor progression and therapeutic implications in breast cancer

AU - Miller, Todd W.

AU - Rexer, Brent N.

AU - Garrett, Joan T.

AU - Arteaga, Carlos L.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Mutations in genes that constitute the phosphatidylinositol 3-kinase (PI3K) pathway occur in >70% of breast cancers. Clinical and experimental evidence suggest that PI3K pathway activation promotes resistance to some of the current breast cancer therapies. PI3K is a major signaling hub downstream of human epidermal growth factor receptor (HER)2 and other receptor tyrosine kinases. PI3K activates AKT, serum/glucocorticoid regulated kinase (SGK), phosphoinositide-dependent kinase 1 (PDK1), mammalian target of rapamycin (mTOR), and several other molecules involved in cell cycle progression and survival. In estrogen receptor (ER)+ breast cancer cells, PI3K activation promotes estrogen-dependent and -independent ER transcriptional activity, which, in turn, may contribute to anti-estrogen resistance. Activation of this pathway also confers resistance to HER2-targeted therapies. In experimental models of resistance to anti-estrogens and HER2 inhibitors, pharmacological inhibition of PI3K/AKT/mTOR has been shown to overcome drug resistance. Early clinical data suggest that combined inhibition of either HER2 or ER plus inhibition of the PI3K pathway might be an effective strategy for treatment of respective HER2+ and ER+ breast cancers resistant to standard therapies. Here, we review alterations in the PI3K pathway in breast cancer, their association with therapeutic resistance, and the state of clinical development of PI3K pathway inhibitors.

AB - Mutations in genes that constitute the phosphatidylinositol 3-kinase (PI3K) pathway occur in >70% of breast cancers. Clinical and experimental evidence suggest that PI3K pathway activation promotes resistance to some of the current breast cancer therapies. PI3K is a major signaling hub downstream of human epidermal growth factor receptor (HER)2 and other receptor tyrosine kinases. PI3K activates AKT, serum/glucocorticoid regulated kinase (SGK), phosphoinositide-dependent kinase 1 (PDK1), mammalian target of rapamycin (mTOR), and several other molecules involved in cell cycle progression and survival. In estrogen receptor (ER)+ breast cancer cells, PI3K activation promotes estrogen-dependent and -independent ER transcriptional activity, which, in turn, may contribute to anti-estrogen resistance. Activation of this pathway also confers resistance to HER2-targeted therapies. In experimental models of resistance to anti-estrogens and HER2 inhibitors, pharmacological inhibition of PI3K/AKT/mTOR has been shown to overcome drug resistance. Early clinical data suggest that combined inhibition of either HER2 or ER plus inhibition of the PI3K pathway might be an effective strategy for treatment of respective HER2+ and ER+ breast cancers resistant to standard therapies. Here, we review alterations in the PI3K pathway in breast cancer, their association with therapeutic resistance, and the state of clinical development of PI3K pathway inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=80755127903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755127903&partnerID=8YFLogxK

U2 - 10.1186/bcr3039

DO - 10.1186/bcr3039

M3 - Review article

VL - 13

JO - Breast Cancer Research

JF - Breast Cancer Research

SN - 1465-5411

IS - 6

M1 - 224

ER -